SolarEdge Technologies (NASDAQ:SEDG) -4.2% in Monday's trading after TD Cowen downgraded shares to Hold from Buy with a $16 ...

TD Cowen downgraded SolarEdge Technologies (NASDAQ:SEDG) from Buy to Hold in a research note, citing ongoing challenges in ...

TD Cowen downgraded SolarEdge (SEDG) to Hold from Buy with a price target of $16, down from $35. The firm cites deteriorating demand in Europe for the downgrade. This will delay a volume, margin ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.68% of ...

Roth MKM analyst Philip Shen maintained a Hold rating on SolarEdge Technologies (SEDG – Research Report) today and set a price target of ...

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar ...

Fintel reports that on October 4, 2024, TD Cowen upgraded their outlook for EVgo (NasdaqGS:EVGO) from Hold to Buy. As of September 25, 2024, the average one-year price target for EVgo is $5.66/share.

TD Cowen upgraded CVS Health (NYSE:CVS) to Buy from Hold and raised its price target to $85 from $59 on Friday, citing an attractive risk-reward setup following several updates related to its ...

Finally, TD Cowen initiates coverage on Chewy (CHWY), giving the pet supplies company a Buy rating and a $38 per share price target. To watch more expert insights and analysis on the latest market ...

Ulta Beauty Inc. was downgraded by TD Cowen Monday, with the analyst firm citing the increasing cost of competition for the specialty retailer. “While [Ulta] remains a category leader with a ...

Fintel reports that on October 4, 2024, TD Cowen upgraded their outlook for CVS Health (SNSE:CVSCL) from Hold to Buy. There are 3,178 funds or institutions reporting positions in CVS Health.

Investing.com -- Analysts at TD Cowen have raised their rating of CVS Health (NYSE:CVS) to "Buy" from "Hold", citing changes to its 2025 Medicare Advantage plan benefits announced earlier this week.